Evidence map›Paper›PMID 37674172›Full record

ArticleMalaria journal2023

Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion.

Freek de Haan, Chanaki Amaratunga, Van Anh Cao Thi, Long Heng Orng, Manithong Vonglokham, Thieu Nguyen Quang, Dysoley Lek, Wouter P C Boon, Arjen M Dondorp, Ellen H M Moors

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Artemisinin-resistant malaria.Clinical microbiology reviews · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 7 countries.

Freek de HaanCopernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands. F.dehaan@uu.nl.
Chanaki AmaratungaMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Van Anh Cao ThiThe University of North Carolina Project in Vietnam, Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, USA.
Long Heng OrngMahidol Oxford Tropical Medicine Research Unit, Epidemiology Department, Mahidol University, Bangkok, Thailand.
Manithong VonglokhamLao Tropical and Public Health Institute, Ministry of Health, Vientiane Capital, Lao PDR.
Thieu Nguyen QuangNational Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam.
Dysoley LekNational Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.
Wouter P C BoonCopernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands.
Arjen M DondorpMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Ellen H M MoorsCopernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands.
Mahidol University · THUtrecht University · NLCambodia National Malaria Center · KHInstitute for Sustainable Development · SINational Institute of Malariology, Parasitology and Entomology · VNPublic Health Institute · USUniversity of North Carolina at Chapel Hill · US

Funding

Foreign, Commonwealth and Development Office 300341-114
6 · The paper itself

Abstract

backgroundThis is a qualitative study to identify implementation challenges for deploying triple artemisinin-based combination therapy (TACT) in the Greater Mekong Subregion (GMS) of Southeast Asia and to explore strategies to overcome these challenges.

methodsIn-depth interviews were conducted in three countries that have repeatedly been confronted with ACT failures: Cambodia, Vietnam, and Lao PDR. Thirty-nine key stakeholders in the healthcare systems in these countries were interviewed. One participatory workshop was conducted in Cambodia, where scenarios for potential TACT deployment were discussed.

resultsThe results section is organized around four strategic themes that emerged from the data: policy support, data and evidence, logistics and operation, and downstream engagement. The study revealed that countries in the GMS currently rely on ACT to eliminate Plasmodium falciparum malaria by 2025. TACT is, however, considered to be a useful backup strategy in case of future treatment failures and to prevent the re-establishment of malaria. The study showed that a major challenge ahead is to engage decision makers and healthcare providers into deploying TACT, given the low case incidence of falciparum malaria in the GMS. Interview respondents were also skeptical whether healthcare providers would be willing to engage in new therapies for a disease they hardly encounter anymore. Hence, elaborate information dissemination strategies were considered appropriate and these strategies should especially target village malaria workers. Respondents proposed several regulatory and programmatic strategies to anticipate the formation of TACT markets in the GMS. These strategies include early dossier submission to streamline regulatory procedures, early stakeholder engagement strategies to shorten implementation timelines, and inclusion of TACT as second-line therapy to accelerate their introduction in case they are urgently needed.

conclusionsThis paper presents a qualitative study to identify implementation challenges for deploying TACT in the GMS and to explore strategies to overcome these challenges. The findings could benefit researchers and decision makers in strategizing towards potential future deployment of TACT in the GMS to combat artemisinin and partner drug resistance.

Indexed as

ArtemisininsMalaria, FalciparumCambodiaHealth PersonnelHumansInformation DisseminationartemisininArtemisininsAntimalarial resistanceImplementation strategiesTriple artemisinin-based combination therapy (TACT)

Identifiers

PMID37674172
PMCPMC10483751
OpenAlexW4386485081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.